Anders Bjartell
Anders Bjartell, MD, PhD, FEBU
Anders Bjartell is Professor of Clinical Urology at Lund University and a Senior Consultant Urologist at Skåne University Hospital in Malmö, Sweden. He has served as Associate Editor of European Urology; President and board member of the EAU Section of Urological Research (ESUR); Chairman of the EAU Research Foundation for 8 years; and a board member of the EAU Guidelines Office since 2016. Bjartell leads a translational prostate cancer research group with extensive experience in biomarker development and has served as national principal investigator for multiple mPC trials.
Disclosures: Consulting, advisory roles, or speaker honoraria from Accord, Astellas, AstraZeneca, Bayer, Ipsen, Johnson & Johnson, Lantheus, Novartis, Pfizer, and Sandoz. Research funding from Astellas, AstraZeneca, Bayer, Curasight, Johnson & Johnson, Novartis, Pfizer, Spectracure, Telix. Cofounder, board member, and shareholder of Glactone Pharma.
View content featuring Bjartell:
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.